Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

Delving into the details, we found 62% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we ...

SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the ...

Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated ...

We recently published an article titled These 10 Stocks Defied Tuesday’s Bloodbath. In this article, we are going to take a ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on 89bio (ETNB – Research Report) yesterday and set a price target of $33.00. The ...

Qure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $70.00 price target on the ...

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Edgewise ...

CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company ...

Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H.C.